Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS7482022 B2
Publication typeGrant
Application numberUS 10/404,964
Publication dateJan 27, 2009
Filing dateApr 1, 2003
Priority dateApr 4, 2002
Fee statusPaid
Also published asCA2481025A1, CN1642531A, CN100335041C, DE60319685D1, DE60319685T2, EP1494654A1, EP1494654B1, US20030215503, WO2003084511A1
Publication number10404964, 404964, US 7482022 B2, US 7482022B2, US-B2-7482022, US7482022 B2, US7482022B2
InventorsTanya Havlir, Kasra Kasraian
Original AssigneePfizer Inc.
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Palatable chewable tablet
US 7482022 B2
Abstract
A palatable chewable tablet is described herein for oral administration of cetirizine dihydrochloride. The formulation is made more palatable by incorporating a combination of a grape flavoring agent with a vanilla flavoring agent.
Images(4)
Previous page
Next page
Claims(1)
1. A palatable chewable bi-layer tablet comprising
(a) a first layer comprising cetirizine dihydrochloride, betacyclodextrin, acesulfame K, colloidal silicon dioxide, microcrystalline cellulose, artificial grape flavor 486939, Pharma Sweet FL Pwd Nat(K), lactose monohydrate, Carmine Dye #09349, FD&C Blue Aluminum Lake and magnesium stearate; and
(b) a second layer comprising mannitol, acesulfame K, artificial grape flavor 486939, Pharma Sweet FL Pwd Nat(K), Carmine Dye #09349, FD&C Blue Aluminum Lake and magnesium stearate;
wherein the percent by tablet weight of each ingredient in said first layer is cetirizine dihydrochloride, 2.22%; betacyclodextrin, 18.33%; acesulfame K, 0.78%; colloidal silicon dioxide, 0.24%; microcrystalline cellulose, 9.75%; artificial grape flavor 486939, 0.13%; Pharma Sweet FL Pwd Nat(K), 0.04%; lactose monohydrate, 12.22%; Carmine Dye #09349, 0.05%; FD&C Blue Aluminum Lake, 0.05%; and magnesium stearate, 0.61%; and the percent by tablet weight of each ingredient in said second layer is mannitol, 53.60%; acesulfame K, 1.04%; artificial grape flavor 486939, 0.17%; Pharma Sweet FL Pwd Nat(K), 0.06%; Carmine Dye #09349, 0.07%; FD&C Blue Aluminum Lake, 0.07%; and magnesium stearate, 0.56%.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims benefit of provisional application No. 60/370,086 filed Apr. 4, 2002.

FIELD OF INVENTION

The present invention relates to an oral chewable tablet, in particular, a chewable tablet that provides a palatable taste to mask the bitter taste of a pharmaceutical agent contained therein.

BACKGROUND

Cetirizine is a generic name for 2-[2-[4-[(4-chlorphenyl)phenylmethyl]-1-piperazinyl]ethoxy]-acetic acid and is typically provided as a dihydrochloride salt. Cetirizine is an orally active and selective H1-receptor antagonist currently prescribed for the treatment of seasonal allergies in patients aged 2 years and older. The current commercial products (Zyrtec™) are available as a white, film-coated, immediate release oral tablet in 5 and 10 mgA strengths and a sweet flavored syrup containing cetirizine hydrochloride at a concentration of 1 mg/ml for pediatric use. European patents Nos. 058,146; 294,993; and 357,369; and also WO 92/02212 describe cetirizine formulations for the controlled or continuous release of cetirizine in the form of tablets and capsules. Oral formulations in the form of a cough syrup are disclosed in WO 94/08551.

For patients, such as children, who have difficulty swallowing conventional tablets or capsules, chewable tablets are widely used in the pharmaceutical industry. In addition, chewable tablets avoid mishaps that may occur with liquids, such as spillage and stains.

One of the drawbacks to oral delivery systems however, is the situation where the drug to be administered is bitter, bad-tasting, odorous or in some manner unpleasant especially to children. Many efforts have been made in the past to “taste mask” these compounds either through elaborate flavor and/or sweetener delivery systems, adsorption of the drug within another material or by encapsulation with a polymer, fat, carbohydrate or other like material. These taste-masking methods basically prevent the bitter tasting components of the drug from contacting the taste-buds during oral ingestion yet break down and release the active upon dissolution in the stomach.

For example, U.S. Pat. No. 4,650,663 discloses the preparation of an oral pharmaceutical delivery system in which an unpleasant tasting anti-tussive such as noscapine, carbetapentane citrate or clophedianol hydrochloride is adsorbed onto magnesium silicate flakes and incorporated into a chewable tablet or lozenge. The adsorbate allegedly masks the bitter taste to an almost negligible level to encourage better patient compliance.

U.S. Pat. No. 6,027,746 discloses a soft chewable gelatin capsule having incorporated therein a drug dispersed in an oral suspension comprising a medicament adsorbate which masks bitter or bad-tasting pharmaceutical actives (such as antihistamines, decongestants and the like).

U.S. Pat. No. 6,270,790 discloses a soft, convex-shaped compressed chewable tablets. Active agents having a bitter or bad taste are masked by coating the drug with a 90:10 to 50:50 polymer blend of cellulose acetate or cellulose acetate butyrate and polyvinyl pyrrolidone or hydroxypropyl cellulose. However, coatings require an additional manufacturing step which adds to the manufacturing costs of the tablet.

U.S. Pat. No. 3,558,600 describes a method for masking the bitter taste of antihistamines belonging to the family of substituted 1-(p-chloro-benzhydryl)-piperazine. This method consists of transforming the active substance in the form of a free base into its long-chain alkyl sulfate salt, such as stearyl sulfate.

Another known method for masking the taste of active ingredients consists of forming an inclusion complex between the active ingredient and a cyclodextrin. In this case, the masking of the taste results from the trapping of the active ingredient, which cannot be released while it is in the mouth. The use of beta-cyclodextrin with cetirizine is described in WO 99/01133.

There still exists a need for a palatable formulation for cetirizine medicaments that assist in compliance especially with children.

SUMMARY

The present invention provides a palatable chewable tablet comprising cetirizine or a pharmaceutically acceptable salt thereof (preferably, the dihydrochloride salt), a sweetener (e.g., acesulfame potassium), a combination of a grape flavoring and a vanilla flavoring in a ratio from about 4:1 to 2:1 (preferably in a ratio from about 3:1 to about 2:1), a cyclodextrin (preferably β-cyclodextrin), and one or more additional excipients (e.g., magnesium stearate, colloidal silicon dioxide, anhydrous lactose, microcrystalline cellulose, microcrystalline cellulose modified with guar gum, croscarmellose sodium, mannitol, sucrose, and dextrinized sucrose).

In a preferred embodiment, a palatable chewable bi-layer tablet is provided comprising (a) a first layer comprising cetirizine or a pharmaceutically acceptable salt thereof (preferably, cetirizine dihydrochloride), a combination of a grape flavoring and a vanilla flavoring in a ratio from about 4:1 to 2:1, beta-cyclodextrin, colorants, one or more additional excipients (e.g., magnesium stearate, colloidal silicon dioxide, anhydrous lactose, microcrystalline cellulose, microcrystalline cellulose modified with guar gum, and croscarmellose sodium); and (b) a second layer comprising mannitol or dextrinized sucrose, a combination of a grape flavoring and a vanilla flavoring in a ratio from about 4:1 to 2:1, colorants, and one or more additional excipients (e.g., magnesium stearate).

DETAILED DESCRIPTION

The present invention relates to a cetirizine tablet that is more palatable for children to encourage better compliance with the physician's recommendations for treatment. Cetirizine is a very bitter tasting drug thus making it difficult to entice children to take the medication. Marketing studies have shown that children 5-12 years of age prefer grape flavors. However, Applicants have discovered that the addition of a vanilla flavoring agent in combination with the grape flavoring agent enhances the grape flavor thus making the tablet even more palatable, especially for children.

Suitable grape-flavoring agents include both natural and artificial flavoring agents and are generally available through several custom manufacturers around the world such as Givaudan (Vernier, Switzerland), Ungerer & Company (Lincoln Park, N.J.), and International Flavors & Fragrances (New York, N.Y.) to name a few. Those skilled in the art will recognize that there are several commercial sources available including custom blenders. A preferred grape flavoring system is Artificial Grape Flavor 486939 from Givaudan. Suitable vanilla-flavoring agents include both natural and synthetic flavoring agents and are available from manufactures around the world such as CHR Hansen, Inc. (Milwaukee, Wis.), Givaudan (Vernier, Switzerland), Ungerer & Company (Lincoln Park, N.J.) and International Flavors & Fragrances (New York, N.Y.) to name a few. Those skilled in the art will recognize that there are several commercial sources available including custom blenders. A preferred vanilla flavoring agent is PharmaSweet Powder Vanilla Flavor Enhancer from CHR Hansen, Inc. The weight ratio of grape to vanilla flavorings is generally in the range from about 4:1 to 2:1, preferably from about 3:1 to about 2:1. The flavoring agents are generally present in the tablet in an amount from about 0.2% to about 1.0%, preferably from 0.3% to about 0.4% by weight. Those skilled in the art will appreciate that the exact amount will vary depending upon the strength of the particular flavoring agent(s) used and will know how to adjust the concentration to achieve the appropriate level of taste. The amount of a particular flavoring agent used may also be limited by the concentrations approved by the regulatory agency (i.e., U.S. Food & Drug Agency) for use in pharmaceutical products. The grape and vanilla flavorings may be blended prior to addition to the pharmaceutical composition or added separately.

Cetirizine belongs to family of substituted benzhydryl piperazines, such as 2-[2-[4-[(4-chlorophenyl)phenylmethyl]-1-piperazinyl]ethoxy]ethanol (hydroxyzine), 2-[2-[4-bis(4-fluorophenyl)methyl]-1-piperazinyl]ethoxy]acetic acid (efletirizine), 1-[(4-chlorophenyl)phenylmethyl]-4-[(3-methylphenyl)-methyl]piperazine (meclizine), or 1-[(4-tert-butyl phenyl)methyl]-4-[(4-chlorophenyl)phenylmethyl]piperazine (buclizine), their optically active isomers, as well as their pharmaceutically acceptable salts. Accordingly, it will be appreciated by those skilled in the art that the present invention may be useful with any of the above-referenced cetirizine family members as well as cetirizine and its pharmaceutically acceptable salts. The amount of cetirizine present in the tablet will vary depending upon the particular dosage requirements. Generally, cetirizine is present in an amount from about 2.0% to about 2.5% by weight of the tablet for a 5 mgA or 10 mgA tablet.

It will also be appreciated by those skilled in the art that the present invention may be useful for other bitter tasting pharmaceutically active ingredients, especially antihistamines and decongestants well-known to those skilled in the art.

The composition may also contain colorants to improve the appearance of the tablet especially since an attractive coloration imparted by a colorant may improve patient compliance. In the present invention, blue and red pigments are typically used to achieve a purple color to match the grape flavoring. The relative amounts of the blue and red colorants will vary depending upon the particular hue of the individual colorants and the resultant purple shade desired. Generally, any red, blue, or purple colorant (natural or synthetic) may be used that is acceptable for use in pharmaceuticals by the regulatory authorities.

Any standard pharmaceutically acceptable excipient can be used in the chewable tablet formulation which provides adequate compression such as diluents (e.g., mannitol, sorbitol, lactose, sucrose, and compressible sugars such as DiPac™ (dextrinized sucrose), available from Austin Products Inc., Holmdel, N.J.), splitting or swelling agents (e.g., polyvinyl polypyrrolidone, croscarmellose sodium (e.g., Ac-Di-Sol™ available from FMC BioPolymer, Philadelphia, Pa.), starches and derivatives, cellulose and derivatives, microcrystalline celluloses, such as Avicel™ PH 101 or Avicel™ CE-15 (a microcrystalline modified with guar gum), both available from FMC BioPolymer, Philadelphia, Pa.), lubricating agents (e.g., magnesium stearate), and flow agents (e.g., colloidal silicon dioxide, such as Cab-O-Sil M5 available from Cabot Corporation, Kokomo, Ind.).

Sweeteners are often used to impart a pleasant flavor to the composition. Suitable sweeteners for use in the present invention include natural sweeteners such as sucrose, dextrose, fructose, invert sugar, mannitol, sorbitol, and the like, as well as synthetic sweeteners such as saccharin, aspartame, acesulfame potassium, cyclamates, and other commercial artificial sweeteners well-known to those of skill in the art. A preferred sweetener is acesulfame K (Sunett™ available from Nutrinova, Frankfort, Germany). The sweetener is added in an amount to achieve a desired sweetness. Typically, the sweetner is present in an amount from about 1.0% to about 5.0%. Those skilled in the part will appreciate that the amount of sweetener may vary depending on the strength of the particular sweetener used and the levels approved by the regulatory authorities for use in pharmaceutical products.

Suitable cyclodextrins for use in the present invention include α, β, or γ cyclodextrins, or an alkylated or hydroxyalkylated derivatives thereof, such as heptakis (2,6-di-o-methyl)-β-cyclodextrin (DIMEB), randomly methylated β-cyclodextrin (RAMEB), and hydroxypropyl β-cyclodextrin (HPβCD). A preferred cyclodextrin is β-cyclodextrin (available from Cerestar USA, Inc., Hammond, Ind. or from Roquette America, Inc., Keokuk. Iowa under the tradename Kleptose™). If desired, the complex of the active substance with cyclodextrin can be prepared in advance, for example, by malaxating the active substance and the cyclodextrin in the presence of water, or by preparing an aqueous solution containing the active substance and the cyclodextrin in the desired molar ratio. Alternatively, the active substance and the cyclodextrin can be simply mixed with other excipients and adjuvants. The molar ratio of active substance to cyclodextrin is preferably from about 1.0 to about 4.0.

A typical manufacturing process for making either a single layer or bi-layer generally involves blending of the desired ingredients to form a uniform distribution of the cetirizine, colorants and flavoring agents. If desired, an inclusion complex of the cetirizine and cyclodextrin (e.g., β-cyclodextrin) may be formed prior to blending into the mixture by malaxating the cetirizine and cyclodextrin in the presence of water in a planetary mixer for about 20 minutes. The mixture is then dried in a drying oven. After drying, the complex is mixed with the color/flavoring blend. The blend is then compressed into a single layer or bi-layer tablet using standard methods well-known to those skilled in the art (e.g., Kilian T-100 tablet press or Courtoy 292/43 rotary bi-layer press). Preferably, excipients having hydroxy groups (e.g., mannitol) that are capable of forming esters with the cetirizine are separated from the cetirizine to avoid formation of cetirizine esters. Therefore, the preferred dosage form is a bi-layer construction where the cetirizine is in a separate layer from sugars such as mannitol. The colorants and flavoring agents may be added to both layers to form a uniform presentation of the tablet.

The tablets may be stored in glass or high density polyethylene (HDPE) bottles with or without a heat induced sealed (HIS) bottle. The bottle may also contain a dessicant. Alternatively, the tablets may be encapsulated into blister packs using standard methods well-known to those skilled in the art.

The following example is provided in order to better teach and disclose a specific embodiment of the present invention and the manner in which the chewable tablets of the present invention may be prepared. Those skilled in the art will recognize that the example is for illustrative purposes only, and that certain variations and changes may be made to alter these formulations in minor degrees. Such variations are still considered to fall within the spirit and scope of the present invention as recited by the claims herein below.

EXAMPLES

Cetirizine Bi-Layer Chewable Tablet:

A bi-layer chewable tablet was prepared using the following two formulations which were prepared separately and then compressed on a bi-layer tablet press.

Formulation 1: Active Layer

Component % by tablet wt
Cetirizine 2HCl 2.22
Betadex, Kleptose ™ 200F 18.33
Acesulfame K 0.78
Colloidal Silicon Dioxide 0.24
Microcrystalline Cellulose 9.75
Artificial Grape Flavor 486939 0.13
(Givaudan Roure)
Pharma Sweet FL PWD Nat (K) 0.04
Lactose monohydrate 12.22
Dye: Carmine ground #09349* 0.05
Dye: FD&C Blue #2 aluminum 0.05
lake*
Magnesium Stearate 0.61

Formulation 2: Placebo Layer

Component % by tablet wt
Mannitol 53.60
Acesulfame Potassium 1.04
Artificial Grape Flavor 486939 0.17
(Givaudan Roure)
Pharma Sweet FL PWD Nat (K) 0.06
Dye: Carmine ground #09349* 0.07
Dye: FD&C Blue #2 aluminum 0.07
lake*
Magnesium Stearate 0.56
*Available from Warner-Jenkinson, South Plainfields, New Jersey.

Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US3558600Jul 28, 1967Jan 26, 1971Abbott LabAlkyl sulfate salts of 1-(p-chlorobenzhydryl)-4-methylhomopiperazines
US4525358May 17, 1983Jun 25, 1985Ucb Pharmaceuticals, Inc.Antihistamines, antiallergens, antispasmodics, bronchodilators
US4650663Dec 19, 1985Mar 17, 1987Warner-Lambert CompanyMagnesium trisilicate suitable for preparation of medicament adsorbates of antitussives
US6027746 *Apr 22, 1998Feb 22, 2000Warner-Lambert CompanyOral drug delivery system comprising a liquid pharmaceutical suspension of an unpleasant tasting drug and an absorber particle (a silica) dispersed in an aqueous or nonaqueous carrier solvent encapsulated in a soft gelatin capsule
US6270790Aug 18, 1998Aug 7, 2001Mxneil-Ppc, Inc.Mannitol, sorbitol, maltitol, dextrose, sucrose, xylitol, or lactose; cellulose, cellulosic derivatives, polyvinyl pyrrolidone, starch, ormodified starch binder
US6455533 *Jul 2, 1998Sep 24, 2002Ucb, S.A.Substituted benzhydrylpiperazines such as cetirizine, hydroxyzine, efletirizine, meclizine and buclizine, the optically active isomers thereof and the pharmaceutically acceptable salts thereof.
US6699502 *Mar 13, 1998Mar 2, 2004Ucb, S.A.Excipient selected from inert matrices, hydrophilic matrices, lipid matrices and mixtures
US20020032217Jul 2, 1998Mar 14, 2002Domenico FanaraPharmaceutical compositions for oral administration, comprising an active substance and a cyclodextrin
US20030035839 *May 15, 2001Feb 20, 2003Peirce Management, LlcMultilayer tablets; side effect reduction
EP0294993A1Jun 1, 1988Dec 14, 1988Pfizer Inc.A generic zero order controlled drug delivery system
EP0357369A2Aug 29, 1989Mar 7, 1990Pfizer Inc.The use of asymetric membranes in delivery devices
WO1992002212A2Aug 1, 1991Feb 8, 1992PfizerUse of interfacially-polymerized membranes in delivery devices
WO1994008551A2Sep 22, 1993Apr 28, 1994Procter & GamblePharmaceutical compositions and methods for treating cold symptoms
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
WO2013185789A1Jun 15, 2012Dec 19, 2013Pharmathen S.A.Pharmaceutical composition containing phosphate binding polymer
Classifications
U.S. Classification424/472, 424/465, 424/464
International ClassificationA61K47/46, A61K47/40, C07D295/08, A61K47/38, A61K47/22, A61K47/04, A61K47/12, A61K47/26, A61K9/00, A61K31/495, A61K9/24, A61K9/28, A61K9/20
Cooperative ClassificationA61K9/2086, A61K31/495, A61K9/282, A61K9/209, A61K9/2826, A61K9/0056
European ClassificationA61K9/00M18B, A61K9/20K4, A61K9/28H4, A61K9/20K4B, A61K31/495, A61K9/28H4B
Legal Events
DateCodeEventDescription
Jun 25, 2012FPAYFee payment
Year of fee payment: 4